The Design and Synthesis of Inhibitors of HIV Budding

HIV-1 remains one of the greatest pandemic diseases with devastating consequences worldwide and there is an urgent need for new classes of antiretrovirals given the increasing frequency of multidrug-resistant HIV-1 strains, relatively poor permeation of some drugs and the high frequency of toxicities to existing drugs. We will exploit our new approach to drug design to synthesise a new class of inhibitors of HIV release and provide a new avenue to accelerating the identification and development of lead compounds to give highly potent and stable drug candidates.